📣 VC round data is live. Check it out!
- Public Comps
- 4basebio
4basebio Valuation Multiples
Discover revenue and EBITDA valuation multiples for 4basebio and similar public comparables like Pacific Edge, ArcticZymes, Vitrafy, SDI Group and more.
4basebio Overview
About 4basebio
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effectively and safely delivering these DNA-based products to patients. The company operates across three geographic segments: Europe, the United States, and the Rest of the World, with the majority of its revenue generated from the United States.
Founded
2019
HQ

Employees
110
Website
Financials (FY)
EV
$70M
Valuation Multiples
Start free trial4basebio Financials
4basebio reported last fiscal year revenue of $1M and negative EBITDA of ($15M).
In the same fiscal year, 4basebio generated $854K in gross profit, ($15M) in EBITDA losses, and had net loss of ($17M).
4basebio P&L
In the most recent fiscal year, 4basebio reported revenue of $1M and EBITDA of ($15M).
4basebio is unprofitable as of last fiscal year, with gross margin of 68%, EBITDA margin of (1176%), and net margin of (1322%).
Financial data powered by Morningstar, Inc.
4basebio Stock Performance
4basebio has current market cap of $97M, and enterprise value of $70M.
Market Cap Evolution
4basebio's stock price is $6.24.
4basebio share price decreased by 8.5% in the last 30 days, and by 58.0% in the last year.
4basebio has an EPS (earnings per share) of $-1.08.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $70M | $97M | -5.2% | -8.5% | -16.5% | -58.0% | $-1.08 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free Trial4basebio Valuation Multiples
4basebio trades at 55.6x EV/Revenue multiple, and (4.7x) EV/EBITDA.
4basebio Financial Valuation Multiples
As of May 9, 2026, 4basebio has market cap of $97M and EV of $70M.
4basebio has a P/E ratio of (5.8x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified 4basebio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


4basebio Margins & Growth Rates
In the most recent fiscal year, 4basebio reported gross margin of 68%, EBITDA margin of (1176%), and net margin of (1322%).
4basebio Margins
4basebio Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
4basebio Operational KPIs
4basebio's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.2M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
4basebio Competitors
4basebio competitors include Pacific Edge, ArcticZymes, Vitrafy, SDI Group, Bioventix, Biohit, Genoway, Bio-Works Technologies, Insight Molecular and AnteoTech.
Most 4basebio public comparables operate across Life Sciences Tools, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 7.2x | 12.1x | (5.0x) | (4.4x) | |||
| 6.9x | 6.4x | 36.2x | 47.9x | |||
| 2106.7x | 85.6x | (11.1x) | (8.1x) | |||
| 1.7x | 1.5x | 9.4x | 7.8x | |||
| 6.4x | 6.6x | 8.2x | 8.7x | |||
| 2.1x | 2.0x | 9.6x | 9.9x | |||
| 1.9x | 1.9x | 7.9x | 11.0x | |||
| 4.5x | — | (16.9x) | — | |||
This data is available for Pro users. Sign up to see all 4basebio competitors and their valuation data. Start Free Trial | ||||||
4basebio Funding History
Before going public, 4basebio raised $38M in total equity funding, across 1 round.
4basebio Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout 4basebio
| When was 4basebio founded? | 4basebio was founded in 2019. |
| Where is 4basebio headquartered? | 4basebio is headquartered in United Kingdom. |
| How many employees does 4basebio have? | As of today, 4basebio has over 110 employees. |
| Who is the CEO of 4basebio? | 4basebio's CEO is Amy Jo Walker. |
| Is 4basebio publicly listed? | Yes, 4basebio is a public company listed on London Stock Exchange. |
| What is the stock symbol of 4basebio? | 4basebio trades under 4BB ticker. |
| When did 4basebio go public? | 4basebio went public in 2021. |
| Who are competitors of 4basebio? | 4basebio main competitors include Pacific Edge, ArcticZymes, Vitrafy, SDI Group, Bioventix, Biohit, Genoway, Bio-Works Technologies, Insight Molecular, AnteoTech. |
| What is the current market cap of 4basebio? | 4basebio's current market cap is $97M. |
| What is the current revenue of 4basebio? | 4basebio's last fiscal year revenue is $1M. |
| What is the current EV/Revenue multiple of 4basebio? | Current revenue multiple of 4basebio is 55.6x. |
| Is 4basebio profitable? | No, 4basebio is not profitable. |
| How many companies 4basebio has acquired to date? | 4basebio hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies 4basebio has invested to date? | 4basebio hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to 4basebio
Lists including 4basebio
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.